Indonesian court strikes down patent evergreening amendment, signaling pushback on drug pricing tactics

An Indonesian Constitutional Court ruled that a recent amendment allowing patent evergreening was unconstitutional, reinstating the original restriction that balances patent rights with public health interests.

The decision came after patient groups and advocates challenged the law, arguing that evergreening lets drugmakers extend monopolies with minor changes and keep prices high.

Advocates say the ruling sends a clear signal to other nations that legal frameworks can be used to curb practices that limit access to affordable medicines.

The court emphasized the need to protect broader public interest, marking a notable regulatory win for those seeking more affordable drug options.